CTOs on the Move


 
An innovative healthcare platform offering quick and simple access to a vast portfolio of mental health providers. Through the mobile app available on both iOS and Android, individuals can access professionals covering over 25 categories of support at low costs with discounted student and standard rates. At zant, we are dedicated to creating a world where mental health services are accessible, affordable, and available to all.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.zant.app
  • 100 Somerset Corporate Boulevard Suite 125
    Bridgewater, NJ USA 08807
  • Phone: 908.224.3735

Executives

Name Title Contact Details
Anthony DiPrizio
Chief Technology Officer Profile

Similar Companies

Grason Stadler

Grason Stadler is a Eden Prairie, MN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Indiana Hemophilia and Thrombosis Center

The Indiana Hemophilia & Thrombosis Center (IHTC) is the only federally recognized comprehensive hemophilia treatment center in Indiana and one of the largest centers in the nation. The IHTC is a 501(c)3 nonprofit entity that is dedicated to providing the best, most comprehensive care to people in Indiana with bleeding or clotting disorders and to their families. The IHTC is both nationally and internationally distinguished as a Center of Excellence for its leadership in bleeding disorder patient care, education and research.

HealthSpace Integrated Solutions

HealthSpace Integrated Solutions is a Glen Allen, VA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

MedHunters

MedHunters is a Toronto, ON-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Kolltan

Kolltan Pharmaceuticals is a private company founded in 2007 that is developing novel monoclonal antibody (mAb) drugs targeting receptor tyrosine kinases (RTKs). Kolltan's primary targets derive from seminal discoveries made in the laboratory of Dr. Joseph Schlessinger, Chairman of the Department of Pharmacology at the Yale School of Medicine, and in Kolltan’s laboratories. Dr. Schlessinger's laboratory has characterized a novel molecular mechanism underlying activation of RTKs providing, for the first time, a clear molecular explanation — at atomic resolution — for the oncogenic activity of mutations that have been identified in a variety of human cancers.